At $54-bn value, interest in GSK’s arm may lead to biggest-ever buyout
GlaxoSmithKline’s (GSK’s) consumer unit is drawing interest from private equity firms in what could lead to the biggest buyout of all time, people with knowledge of the matter said.
The drugmaker’s advisers are informally fielding interest in the operations alongside preparations for a listing, said the people in the know. Advent International, CVC Capital Partners and KKR & Co are among potential suitors evaluating the business, they said.
Blackstone, Carlyle Group, and Permira are also seen as likely suitors for the consumer arm, which could be valued at £40 billion ($54 billion) or more in any deal, the people said. The unit, with brands including Panadol painkillers, Tums antacids and Centrum vitamins, could also attract some of the world’s biggest pharmaceutical and consumer-goods companies.
Glaxo’s planned split into separate pharmaceutical and consumer businesses has been in the works for almost three years. Chief Executive Officer Emma Walmsley is fending off pressure from activist investors Elliott Investment Management and Bluebell Capital Partners for faster change. The company has fallen behind rivals such as AstraZeneca in developing innovative drugs, and was sidelined in the race to create Covid-19 shots despite being the world’s biggest vaccine maker.
Glaxo said Tuesday that it’s on track to demerge the consumer unit in mid-2022 and repeated that the board will evaluate any options that would boost shareholder value. Glaxo shares rose as much as 4.8% in London trading Tuesday. The stock was up 1.26 per cent at 8.38 pm IST.
The consumer business has “strong growth prospects which will be further enhanced by its access to the capital markets and ability to set its own strategy” as an independent company, Glaxo said.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
